Schrödinger to Present Preclinical Data at AACR Annual Meeting
Schrödinger (SDGR) announced upcoming presentations of preclinical data for two investigational cancer treatments at the AACR Annual Meeting 2025 in Chicago. The company will present data on SGR-3515, a Wee1/Myt1 inhibitor, showing improved therapeutic results through optimized intermittent dosing in preclinical oncology models. A Phase 1 clinical trial for SGR-3515 is ongoing, with initial data expected in H2 2025.
Additionally, SDGR will present findings on a machine learning model that predicts drug combination responses with Wee1 inhibitors. The company will also showcase the first preclinical data for SGR-4174, their SOS1 inhibitor targeting KRAS-driven cancers. The data suggests SGR-4174 has a differentiated profile supporting its development for KRAS mutant cancers and rare diseases arising from KRAS pathway mutations.
Schrödinger (SDGR) ha annunciato prossime presentazioni di dati preclinici per due trattamenti oncologici in fase di sperimentazione al AACR Annual Meeting 2025 a Chicago. L'azienda presenterà dati su SGR-3515, un inibitore di Wee1/Myt1, che mostra risultati terapeutici migliorati grazie a un dosaggio intermittente ottimizzato in modelli oncologici preclinici. È in corso una sperimentazione clinica di Fase 1 per SGR-3515, con i dati iniziali attesi nel secondo semestre del 2025.
Inoltre, SDGR presenterà i risultati di un modello di apprendimento automatico che prevede le risposte alle combinazioni di farmaci con inibitori di Wee1. L'azienda mostrerà anche i primi dati preclinici per SGR-4174, il loro inibitore di SOS1 che mira ai tumori guidati da KRAS. I dati suggeriscono che SGR-4174 ha un profilo differenziato che supporta il suo sviluppo per i tumori mutanti KRAS e le malattie rare derivanti da mutazioni della via di KRAS.
Schrödinger (SDGR) anunció próximas presentaciones de datos preclínicos para dos tratamientos contra el cáncer en investigación en la AACR Annual Meeting 2025 en Chicago. La compañía presentará datos sobre SGR-3515, un inhibidor de Wee1/Myt1, que muestra resultados terapéuticos mejorados a través de una dosificación intermitente optimizada en modelos oncológicos preclínicos. Un ensayo clínico de Fase 1 para SGR-3515 está en curso, con datos iniciales esperados en la segunda mitad de 2025.
Además, SDGR presentará hallazgos sobre un modelo de aprendizaje automático que predice las respuestas a combinaciones de fármacos con inhibidores de Wee1. La compañía también mostrará los primeros datos preclínicos para SGR-4174, su inhibidor de SOS1 dirigido a cánceres impulsados por KRAS. Los datos sugieren que SGR-4174 tiene un perfil diferenciado que apoya su desarrollo para los cánceres mutantes de KRAS y enfermedades raras derivadas de mutaciones en la vía de KRAS.
슈뢰딩거 (SDGR)는 시카고에서 열리는 AACR 연례 회의 2025에서 두 가지 임상 전 암 치료법에 대한 발표를 예고했습니다. 회사는 SGR-3515에 대한 데이터를 발표할 예정이며, 이는 Wee1/Myt1 억제제로, 최적화된 간헐적 투여를 통해 임상 전 종양학 모델에서 개선된 치료 결과를 보여줍니다. SGR-3515에 대한 1상 임상 시험이 진행 중이며, 초기 데이터는 2025년 하반기에 예상됩니다.
또한, SDGR은 Wee1 억제제와의 약물 조합 반응을 예측하는 기계 학습 모델에 대한 결과를 발표할 것입니다. 이 회사는 KRAS에 의해 유도되는 암을 목표로 하는 그들의 SOS1 억제제인 SGR-4174에 대한 최초의 임상 전 데이터를 선보일 것입니다. 데이터는 SGR-4174가 KRAS 변이 암 및 KRAS 경로 변이로 인한 희귀 질환의 개발을 지원하는 차별화된 프로필을 가지고 있음을 시사합니다.
Schrödinger (SDGR) a annoncé des présentations à venir de données précliniques pour deux traitements expérimentaux contre le cancer lors de la AACR Annual Meeting 2025 à Chicago. L'entreprise présentera des données sur SGR-3515, un inhibiteur de Wee1/Myt1, montrant des résultats thérapeutiques améliorés grâce à un dosage intermittent optimisé dans des modèles d'oncologie préclinique. Un essai clinique de phase 1 pour SGR-3515 est en cours, avec des données initiales attendues au second semestre 2025.
De plus, SDGR présentera des résultats sur un modèle d'apprentissage automatique qui prédit les réponses aux combinaisons de médicaments avec des inhibiteurs de Wee1. L'entreprise mettra également en avant les premières données précliniques pour SGR-4174, son inhibiteur de SOS1 ciblant les cancers induits par KRAS. Les données suggèrent que SGR-4174 possède un profil différencié soutenant son développement pour les cancers mutés de KRAS et les maladies rares résultant de mutations dans la voie de KRAS.
Schrödinger (SDGR) hat die bevorstehenden Präsentationen von präklinischen Daten für zwei experimentelle Krebsbehandlungen auf dem AACR Annual Meeting 2025 in Chicago angekündigt. Das Unternehmen wird Daten zu SGR-3515 präsentieren, einem Wee1/Myt1-Inhibitor, der verbesserte therapeutische Ergebnisse durch optimierte intermittierende Dosierung in präklinischen Onkologie-Modellen zeigt. Eine Phase-1-Studie für SGR-3515 ist im Gange, mit ersten Daten, die für das zweite Halbjahr 2025 erwartet werden.
Darüber hinaus wird SDGR Ergebnisse eines maschinellen Lernmodells präsentieren, das die Reaktionen auf Arzneimittel-Kombinationen mit Wee1-Inhibitoren vorhersagt. Das Unternehmen wird auch die ersten präklinischen Daten für SGR-4174 vorstellen, seinen SOS1-Inhibitor, der auf KRAS-gesteuerte Krebserkrankungen abzielt. Die Daten deuten darauf hin, dass SGR-4174 ein differenziertes Profil aufweist, das seine Entwicklung für KRAS-mutierte Krebserkrankungen und seltene Krankheiten, die aus Mutationen im KRAS-Signalweg resultieren, unterstützt.
- Phase 1 clinical trial for SGR-3515 is actively progressing
- SGR-3515 showed improved therapeutic results through optimized dosing
- Machine learning model successfully identified new synergistic drug combinations
- First preclinical data for SGR-4174 demonstrates differentiated profile for KRAS-driven cancers
- Both drug candidates are still in early development stages
- Clinical efficacy data not yet available for either compound
Presentations include preclinical data on Wee1/Myt1 inhibitor SGR-3515 and SOS1 inhibitor SGR-4174
The SGR-3515 presentation will include data demonstrating that an optimized, intermittent dosing schedule of SGR-3515 resulted in an improved therapeutic index in preclinical oncology models. Preclinical data also showed that SGR-3515 has a differentiated profile supporting continued development as a potential therapy for patients with advanced solid tumors. A Phase 1 clinical trial in this patient population is ongoing, and Schrödinger expects to report initial clinical data from the trial in the second half of 2025.
Data will also be presented on the development of a machine learning model that predicts the response to drug combinations between Wee1 and other drugs in a large group of cell line models in selected cancer types. Additionally, the model identified several compounds as synergistic with Wee1 in new cancer settings which may be of future interest.
The SGR-4174 presentation will include data characterizing SGR-4174 in preclinical oncology models. The SOS1 protein plays a critical role in the activation and regulation of the KRAS gene. Inhibition of SOS1 is considered a potential therapeutic combination strategy for the treatment of KRAS-driven cancers. Preclinical data suggest SGR-4174 has a differentiated profile and support its continued development as a potential therapy for patients with KRAS mutant cancers and in rare diseases arising from KRAS pathway mutations. This is the first preclinical data presentation for SGR-4174.
Details of the data presentations are as follows:
Presentation Title: Optimization of therapeutic index of SGR-3515, a first-in-class Wee1/Myt1 inhibitor through intermittent dosing for monotherapy and combination with chemotherapy in xenograft tumor models
Abstract Number: #3025
Presentation Date and Time: Monday, April 28, 2025, 2-5PM CST (3-6PM ET)
Location: Poster Section 20
Session Title: Kinase and Phosphatase Inhibitors 2
Presentation Title: Machine learning-based combination prediction for Wee1 inhibitor
Abstract Number: #3660
Presentation Date and Time: Monday, April 28, 2025, 2-5PM CST (3-6PM ET)
Location: Poster Section 45
Session Title: Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery
Presentation Title: Preclinical characterization of SGR-4174, a potent and selective SOS1 inhibitor for the treatment of pan KRAS mutant cancers in combination with KRAS pathway inhibitors
Abstract Number: #4376
Presentation Date and Time: Tuesday, April 29, 2025, 9AM-12PM CST (10AM-1PM ET)
Location: Poster Section 21
Session Title: RAS Inhibitors
About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding the potential advantages of Schrödinger’s computational platform, the clinical potential and favorable properties of SGR-3515, its Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, the potential for SGR-3515 to be used for the treatment of advanced solid tumors, the potential for SGR–4174 to be used for the treatment of KRAS-driven cancers, and the timing, progress, and results of clinical trials for its product candidates, including SGR-3515. Statements including words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger’s control, including the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical and early clinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of clinical trials and applications for marketing approvals and the ability to retain and hire key personnel on its business and other risks detailed under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324582138/en/
Matthew Luchini (Investors)
matthew.luchini@schrodinger.com
917-719-0636
Allie Nicodemo (Media)
allie.nicodemo@schrodinger.com
617-356-2325
Source: Schrödinger
FAQ
When will Schrödinger (SDGR) report initial clinical data for SGR-3515?
What are the two drug candidates SDGR is presenting at AACR 2025?
What is the target indication for Schrödinger's SGR-3515?
What is the therapeutic focus of SDGR's SGR-4174 inhibitor?
